

Transtema Q2 Preview - Expect a Modest Q2 but Strong Deal Flow Points Towards Solid 2025

Redeye raised its Base Case and 2025 forecasts for Transtema following the recently announced large deal. At the same time, we expect a modest Q2 report. Nevertheless, we believe Transtema is set for solid growth and margin improvements from 2025 and beyond as several large deals kick in.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Transtema Q2 Preview - Expect a Modest Q2 but Strong Deal Flow Points Towards Solid 2025